Abstract
Regulated exocytosis establishes a narrow fusion pore as the initial aqueous connection to the extracellular space, through which small transmitter molecules such as ATP can exit. Co-release of larger peptides and hormones like insulin requires further expansion of the pore. There is evidence that pore expansion is regulated and can fail in type-2 diabetes and neurodegenerative disease. Here we report that the cAMP-sensor Epac2 (Rap-GEF4) controls fusion pore behavior by acutely recruiting two pore-restricting proteins, amisyn and dynamin-1, to the exocytosis site in insulin-secreting beta-cells. cAMP elevation leads to pore expansion and peptide release, but not when Epac2 is inactivated pharmacologically or in Epac2−/− mice. Conversely, overexpression of Epac2 impedes pore expansion. Widely used antidiabetic drugs (GLP-1 agonists and sulfonylureas) activate this pathway and thereby paradoxically restrict hormone release. We conclude that Epac2/cAMP controls fusion pore expansion and thus the balance of hormone and transmitter release during insulin granule exocytosis.
| Original language | English |
|---|---|
| Pages (from-to) | 314A-314A |
| Number of pages | 1 |
| Journal | Biophysical Journal |
| Volume | 116 |
| Issue number | 3, Supplement 1 |
| DOIs | |
| Publication status | Published - 2019 |
| Externally published | Yes |
| Event | 63rd Annual Meeting of the Biophysical-Society, MAR 02-06, 2019, Baltimore, MD - Duration: 1 Jan 2019 → … |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver